<DOC>
	<DOC>NCT00460798</DOC>
	<brief_summary>This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before. The aim of the trial is to increase knowledge about quality of life, safety, efficacy and tolerability under conditions of routine use of Sutent. The individual observation period of each patient will be 1 year.</brief_summary>
	<brief_title>SUTENTÂ® In The First Line Treatment Of Renal Cell Carcinoma</brief_title>
	<detailed_description>The Statistical Analysis Plan provides detailed specification of the analysis</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Firstline treatment in patients with metastatic renal cell carcinoma Any previous systemic therapy of renal cell carcinoma except for adjuvant treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Sunitinib</keyword>
	<keyword>kidney diseases</keyword>
	<keyword>urogenital neoplasms</keyword>
	<keyword>kidney cancer</keyword>
</DOC>